Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $166.9 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” GILD fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
However, the stock currently trades 16.7% below its 52-week high of $157.29 recorded on Feb. 11. GILD has declined 12% over the past three months, notably underperforming the State Street Health Care Select Sector SPDR ETF’s (XLV) 7.7% fall during the same time frame.
www.barchart.com In the longer term, GILD has delivered a different performance. The stock rose 19.1% over the past 52 weeks, outperforming 11.5% rise of XLV over the same period. GILD has been trading below its 200-day moving average since last year and below its 50-day moving average since the end of May.
www.barchart.com On May 7, GILD stock declined 1.6% following the release of its Q1 2026 earnings. The company’s revenue for the quarter amounted to $7 billion and surpassed the Street’s estimates. Moreover, its adjusted EPS for the quarter came in at $2.03, also coming in on top of Wall Street’s forecasts. Gilead expects full-year results to range from a loss of $1.05 per share to a loss of $0.65 per share.
When stacked against its rival, Amgen Inc. (AMGN) has grown 14.2% over the past year, underperforming GILD.
Wall Street continues to favor the stock highly. Among the 32 analysts tracking GILD, the overall consensus stands at a “Strong Buy.” Its mean price target of $159.20 suggests 21.4% upside potential from current price levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
This High-Yield Home Improvement Stock Just Hiked Its Dividend by 4.2% FLNC Stock Skyrockets as Fluence Energy Partners With Nvidia and Siemens PANW Stock Gains as NATO Selects Palo Alto Networks for Cybersecurity Partnership FedEx Freight Stock Starts Trading June 1 as a Member of the S&P 500. How to Play FDXF Here.